Increased frequency of CD4+ PD-1+ HLA-DR+ T cells is associated with disease progression in CLL

Lauren Elston1, Chris Fegan1, Robert Hills1

  • 1Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK.

Insights

Abnormal T cell expansions in chronic lymphocytic leukemia (CLL) correlate with disease progression. Specific CD4+ and CD8+ T cell subsets, particularly CD4+ PD-1+ HLA-DR+ T cells, serve as key biomarkers for risk stratification in CLL patients.

Area of Science:

  • Immunology
  • Hematology
  • Oncology

Background:

  • Chronic lymphocytic leukemia (CLL) is characterized by abnormal T cell expansions.
  • These T cell abnormalities are often linked to disease progression.

Purpose of the Study:

  • To identify specific T cell populations associated with CLL progression.
  • To evaluate T cell phenotypic markers as potential biomarkers for risk stratification in CLL.

Main Methods:

  • Flow cytometry analysis of T cells from 74 CLL patients and 14 healthy controls.
  • Utilized 11 phenotypic markers to characterize T cell subsets.
  • Multivariate analysis to correlate T cell subset frequencies with progression-free survival.

Main Results:

  • CLL patients exhibit increased frequencies of CD4+ and CD8+ memory T cells with exhaustion, activation, and senescence markers.
  • High frequencies of four specific T cell subsets (three CD8+, one CD4+) were associated with shorter progression-free survival.
  • CD4+ HLA-DR+ PD-1+ T cells emerged as a significant prognostic biomarker, enabling high- and low-risk stratification.

Conclusions:

  • Specific T cell subsets, notably CD4+ PD-1+ HLA-DR+ T cells, are pivotal in CLL pathology.
  • Percentage CD8+ and CD4+ PD-1+ HLA-DR+ T cells offer simple, independent biomarkers for CLL patient risk stratification.
  • These findings underscore the critical role of T cells in modulating CLL progression.